These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39172439)

  • 1. Ready, AIM, stop: ibrutinib plus venetoclax in MCL.
    Wallace DS; Barr PM
    Blood; 2024 Aug; 144(8):800-802. PubMed ID: 39172439
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnostically challenging immunophenotypic shift in mantle cell lymphoma following ibrutinib and venetoclax therapy.
    Leitinger EJ; Wright RM; Nelson N; Anderson MA; Juneja S
    Pathology; 2021 Dec; 53(7):926-929. PubMed ID: 33947523
    [No Abstract]   [Full Text] [Related]  

  • 3. Fatal splenic rupture after discontinuing treatment by ibrutinib and venetoclax in relapse/refractory mantle cell lymphoma.
    Roulin L; Haioun C; Lemonnier F
    Ann Hematol; 2021 May; 100(5):1345-1347. PubMed ID: 33655374
    [No Abstract]   [Full Text] [Related]  

  • 4. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
    Wang M; Ramchandren R; Chen R; Karlin L; Chong G; Jurczak W; Wu KL; Bishton M; Collins GP; Eliadis P; Peyrade F; Lee Y; Eckert K; Neuenburg JK; Tam CS
    J Hematol Oncol; 2021 Oct; 14(1):179. PubMed ID: 34717692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
    Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
    N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
    Rogers KA; Huang Y; Ruppert AS; Awan FT; Heerema NA; Hoffman C; Lozanski G; Maddocks KJ; Moran ME; Reid MA; Lucas M; Woyach JA; Whitlow WT; Jones JA; Byrd JC
    Blood; 2018 Oct; 132(15):1568-1572. PubMed ID: 30111609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperleukocytosis increases risk of fatal hyperkalemia with new ibrutinib/venetoclax regimen for refractory mantle cell lymphoma.
    Verma A; Mbughuni M; Mariash E; Mesa H
    J Chemother; 2019; 31(7-8):428-431. PubMed ID: 31738653
    [No Abstract]   [Full Text] [Related]  

  • 8. Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
    Handunnetti SM; Anderson MA; Burbury K; Thompson PA; Burke G; Bressel M; Di Iulio J; Hicks RJ; Westerman D; Lade S; Pott C; Agarwal R; Koldej R; Ritchie D; Dreyling M; Dawson MA; Dawson SJ; Seymour JF; Roberts AW; Tam CS
    Blood; 2024 Aug; 144(8):867-872. PubMed ID: 38662991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.
    Jiang H; Lwin T; Zhao X; Ren Y; Li G; Moscinski L; Shah B; Tao J
    Br J Haematol; 2019 Jan; 184(2):298-302. PubMed ID: 29383700
    [No Abstract]   [Full Text] [Related]  

  • 10. The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
    Tarantelli C; Zhang L; Curti E; Gaudio E; Spriano F; Priebe V; Cascione L; Arribas AJ; Zucca E; Rossi D; Stathis A; Bertoni F
    Haematologica; 2019 Jul; 104(7):e307-e309. PubMed ID: 30679329
    [No Abstract]   [Full Text] [Related]  

  • 11. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
    Le Gouill S; Morschhauser F; Chiron D; Bouabdallah K; Cartron G; Casasnovas O; Bodet-Milin C; Ragot S; Bossard C; Nadal N; Herbaux C; Tessoulin B; Tchernonog E; Rossi C; McCulloch R; Gastinne T; Callanan MB; Rule S
    Blood; 2021 Feb; 137(7):877-887. PubMed ID: 33181832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
    Hillmen P; Rawstron AC; Brock K; Muñoz-Vicente S; Yates FJ; Bishop R; Boucher R; MacDonald D; Fegan C; McCaig A; Schuh A; Pettitt A; Gribben JG; Patten PEM; Devereux S; Bloor A; Fox CP; Forconi F; Munir T
    J Clin Oncol; 2019 Oct; 37(30):2722-2729. PubMed ID: 31295041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.
    Agarwal R; Chan YC; Tam CS; Hunter T; Vassiliadis D; Teh CE; Thijssen R; Yeh P; Wong SQ; Ftouni S; Lam EYN; Anderson MA; Pott C; Gilan O; Bell CC; Knezevic K; Blombery P; Rayeroux K; Zordan A; Li J; Huang DCS; Wall M; Seymour JF; Gray DHD; Roberts AW; Dawson MA; Dawson SJ
    Nat Med; 2019 Jan; 25(1):119-129. PubMed ID: 30455436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells.
    Jin F; He L; Chen Y; Tian W; Liu L; Ge L; Qian W; Xia L; Yang M
    Braz J Med Biol Res; 2024; 57():e13278. PubMed ID: 39383379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.
    Melani C; Lakhotia R; Pittaluga S; Phelan JD; Huang DW; Wright G; Simard J; Muppidi J; Thomas CJ; Ceribelli M; Tosto FA; Yang Y; Xu W; Davies-Hill T; Pack SD; Peer CJ; Arisa O; Mena E; Lindenberg L; Bergvall E; Portell CA; Farah RJ; Lee ST; Pradhan A; Morrison C; Tadese A; Juanitez AM; Lu C; Jacob A; Simmons H; Figg WD; Steinberg SM; Jaffe ES; Roschewski M; Staudt LM; Wilson WH
    N Engl J Med; 2024 Jun; 390(23):2143-2155. PubMed ID: 38899693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia.
    Hampel PJ; Rabe KG; Call TG; Ding W; Leis JF; Kenderian SS; Muchtar E; Wang Y; Koehler AB; Parrondo R; Schwager SM; Shi M; Braggio E; Slager SL; Kay NE; Parikh SA
    Br J Haematol; 2022 Oct; 199(2):239-244. PubMed ID: 35841338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.
    Goto H; Ito S; Kizaki M; Yamaguchi M; Fukuhara N; Kato K; Saito T; Terui Y; Okubo S; Soshin T; Zeng J; Honda H; Badawi M; Ross JA; Izutsu K
    Int J Clin Oncol; 2024 Feb; 29(2):232-240. PubMed ID: 38157190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib and Venetoclax for First-Line Treatment of CLL.
    Jain N; Keating M; Thompson P; Ferrajoli A; Burger J; Borthakur G; Takahashi K; Estrov Z; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Sasaki K; Kanagal-Shamanna R; Patel K; Jorgensen J; Garg N; Wang X; Sondermann K; Cruz N; Wei C; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda W
    N Engl J Med; 2019 May; 380(22):2095-2103. PubMed ID: 31141631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma.
    Zhou X; Steinhardt MJ; Düll J; Krummenast F; Danhof S; Meckel K; Nickel K; Grathwohl D; Leicht HB; Rosenwald A; Einsele H; Rasche L; Kortüm M
    Eur J Haematol; 2020 Apr; 104(4):352-355. PubMed ID: 31922303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.
    Agarwal R; Dawson MA; Dreyling M; Tam CS
    Leuk Lymphoma; 2018 Dec; 59(12):2769-2781. PubMed ID: 29912596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.